Reading Time: 2 minutesIntroduction Congenital heart disease (CHD) remains a significant health concern among pediatric populations, often leading to growth impairments due to the increased metabolic demands and chronic illness associated with the condition. Saizen, a recombinant human growth hormone (rhGH), has emerged as a potential therapeutic agent to address growth deficits in these children. This article delves into the use of Saizen in children with CHD, focusing on its effects on growth and overall health outcomes. Understanding Congenital Heart Disease and Growth Congenital heart disease encompasses a range of structural abnormalities present at birth, which can severely impact a child's cardiovascular function … Continue reading
-
Injectable Sermorelin
-
Search -
Archives
- May 2025
- April 2025
- March 2025
- February 2025
- April 2024
- March 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- February 2019
- January 2019
-
HGH Decline Charts
-
Sermorelin Products
-
Sermorelin Health